In the results of a phase I trial that were presented at the American Society of Clinical Oncology (ASCO) annual meeting in 2012, the antibody was studied in nine patients with a variety of tumor types, including two patients with melanoma. The drug was well-tolerated and generated antitumor activity in three different doses.
They won't work....At least that is what I was told....... BP smoke. They are way behind...Can't catch up. One failed last week, no benefits in a PHIII...None...Program stopped.
News 
Market Data 
Discover 
